CXCR4-Dependent Immuno- and Antiangiogenic Therapy against Hepatocellular Carcinoma
DBPR807, a highly selective, safe, and potent CXCR4 antagonist, possesses in vivo efficacy under various HCC settings with supreme benefits on combination therapy, whereby it can significantly synergize with not only antiangiogenic therapy (sorafenib) but also immunotherapy (anti–PD-1) to further extend overall survival. DBPR807 can significantly suppress tumor growth, prevent metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. Our results suggest the clinical potential of DBPR807 for the treatment of HCC.
National Health Research Institutes (NHRI) is a medical and health research organization in Taiwan, established as a public-funded foundation. Its main research areas include medicine, pharmaceuticals, public health, and other life sciences, as well as related technologies such as vaccine development.
Development of an Implantable Bioelectronic Platform for the Peripheral Neuromuscular System Regeneration
Using Generative Deep Learning to Predict Drug Response and Survival, a nd Automatically Match Clinical Trials for Advanced Lung Cancer.
Precision nano-vesicle therapy: Missile-like extracellular vesicles attack on infectious microbes
Therapeutic Humanized Anti-CD24 Monoclonal Antibody for Precision Targeted Therapy of Triple-Negative Breast Cancer
Technology maturity：Prototype
Exhibiting purpose：Display of scientific results
Trading preferences：Negotiate by self
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!